On June 29, 2020, HHS announced an agreement to secure more than 500,000 treatment courses of the drug remdesivir for the United States from Gilead Sciences through September, allowing American hospitals to purchase the drug at the Wholesale Acquisition Cost (WAC) of approximately $3,200 per treatment course.  Additional supplies of remdesivir have been obtained for clinical trials. HHS will allocate the remdesivir to state health departments based on the state’s COVID-19 hospital burden, and health departments will allocate it to hospitals. The delivery of the purchased remdesivir will be streamlined, shipping directly from AmerisourceBergen to hospitals, about every two weeks.  Previously, remdesivir has been donated by Gilead Sciences to HHS; however, the last of HHS’s donated supply was distributed to hospitals earlier this week.